Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Amortization of Deferred Charges (2021 - 2022)

SAB Biotherapeutics' Amortization of Deferred Charges history spans 2 years, with the latest figure at $24717.0 for Q3 2022.

  • For Q3 2022, Amortization of Deferred Charges fell 40.09% year-over-year to $24717.0; the TTM value through Sep 2022 reached $138939.0, changed N/A, while the annual FY2021 figure was $164983.0, 0.03% changed from the prior year.
  • Amortization of Deferred Charges reached $24717.0 in Q3 2022 per SABSW's latest filing, down from $31809.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $41259.0 in Q1 2021 to a low of $24717.0 in Q3 2022.